medigraphic.com
ISSN 1527-3172 (Digital)

2010, Número 3

<< Anterior Siguiente >>

MEDICC Review 2010; 12 (3)


Three-pronged innovation to improve care for acute myocardial infarction patients in Cuba

Giraldo G

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 11-16
Archivo PDF: 221.80 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mackay J, Mensah G. The Atlas of Heart Disease and Stroke. [Internet]. Geneva: World Health Organization; 2004. Types of Cardiovascular Disease; [cited 2010 May 15]; p. 18. Available from: http://www.who.int/cardiovascular_diseases/ en/cvd_atlas_01_types.pdf

  2. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. Br Med Bull. 2009;92:7–32.

  3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine. 2006 Nov;3(11):e442.

  4. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115.

  5. Gaziano TA. Cardiovascular disease in the developing world and its costeffective management. Cardiology Rounds [Internet]. 2005 Feb [cited 2010 May 27];9(2) 6 p. Available from: http://www.cardiologyrounds.org/crus/cardious_ 0205.pdf

  6. Armas N, Hernández Y, Dueñas A, de la Noval R, Castillo A. Cardiovascular Risk among Older Women in a Havana Health Area. MEDICC Rev. 2008;10(2):21–6.

  7. Cooper RS, Orduñez P, Iraola Ferrer MD, Munoz JL, Espinosa-Brito A. Cardiovascular disease and associated risk factors in Cuba: prospects for prevention and control. Am J Public Health. 2006;96(1):94–101.

  8. Reed G. Chronic Vascular Diseases in Cuba: Strategies for 2015. MEDICC Rev. 2008;10(2):5–7.

  9. Franco M, Orduñez P, Caballero B, Tapia Granados JA, Lazo M, Bernal JL, et al. Impact of energy intake, physical activity, and population-wide weight loss on cardiovascular disease and diabetes mortality in Cuba, 1980–2005. Am J Epidemiol. 2007;166(12):1374–80.

  10. Hernández A, Dueñas A, Llerena L. Programa nacional de prevención, diagnóstico, evaluación, tratamiento y rehabilitación de la cardiopatía isquémica. República de Cuba. Havana: Ministry of Public Health (CU); 2000. 39 p.

  11. Interviews conducted with Dr Lorenzo Llerena, Dr Alfredo Dueñas, Dr Nurys Armas, Dr Reynaldo de la Noval and Dr Yanela Ortega at Department of Preventive Cardiology, Cardiology and Cardiovascular Surgery Institute. Havana, Cuba. March 8–12, 2010.

  12. Fernández A, Gálvez AM, Castillo A. Costo institucional del infarto agudo del miocardio en el Instituto de Cardiología y Cirugía Cardiovascular. Rev Cubana de Salud Pública. 2008;34(4):8.

  13. Cabrera JO, Palacio H. Factores asociados a mortalidad intrahospitalaria en el infarto agudo del miocardio con supradesnivel del ST. Rev Cubana Invest Biomed. 2008 Jan–Mar;27(1):1–10.

  14. Based on the range of the ST segment elevation visible in the electrocardiogram, there are two main types of AMI: with ST elevation (STEMI) and without (NSTEMI). STEMI is a severe infarct caused by a prolonged blockage of the blood supply and affecting a large area of the heart, posing substantial risk of death and disability. Each type of AMI has its own separate and distinct treatment guidelines and STEMI is the type of infarct that benefi ts the most from immediate reperfusion therapy.

  15. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA. 2007;297(17):1892–900.

  16. The American College of Cardiology, the American Heart Association and the European Society of Cardiology endorse reperfusion as a class 1 recommendation, signifying suffi cient evidence that the treatment is benefi cial, useful and effective. See ref. 19 and 34.

  17. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol. 2006;111(2):189–94.

  18. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007;34(3):318–27.

  19. Van de Werf F, Bax J, Betriu A, Blomstrom–Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909–45.

  20. Walley T, Dundar Y, Hill R, Dickson R. Superiority and equivalence in thrombolytic drugs: an interpretation. QJM. 2003 Feb;96(2):155–60.

  21. Nazzal NC, Campos TP, Corbalán HR, Lanas ZF, Bartolucci JJ, Sanhueza CP, et al. The impact of Chilean health reform in the management and mortality of ST elevation myocardial infarction (STEMI) in Chilean hospitals. Rev Med Chil. 2008 Oct;136(10):1231–9.

  22. Raffo C, Bartolucci J, Corbalán R, Aninat M, Torres H, Prieto JC, et al. Utilidad de la terapia trombolítica con estreptokinasa a dosis baja en infarto agudo del miocardio. Rev Med Chil. 2006;134(10):1249–57.

  23. Hermentin P, Cuesta-Linker T, Weisse J, Schmidt K, Knorst M, Scheld M, et al. Comparative analysis of the activity and content of different streptokinase preparations. Eur Heart J. 2005 May;26(9):933–40.

  24. At the time of the study, Streptase was registered with Hoeschst–Roussel, Germany; today Aventis, Behring GmbH, Germany.

  25. The TERIMA Group Investigators. Multicenter, randomised, comparative study of recombinant vs. natural streptokinases in acute myocardial infarct. Thromb Haemost. 1999;82:1605–9.

  26. The TERIMA Group of Investigators. TERIMA-2: national extension of thrombolytic treatment with recombinant streptokinase in acute myocardial infarct in Cuba. Thromb Haemost. 2000;84:949–54.

  27. Betancourt BY, Marrero-Miragaya MA, Jiménez-López G, Valenzuela-Silva C, García-Iglesias E, Hernández-Bernal F, et al. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 2005 Nov 2;5:5.

  28. Pérez-Oliva JF, Parodis Y, Benitez O, Sotolongo R, Vigoa ME, Raola ME, et al. Use of Recombinant streptokinase for hemodialysis catheter recovery. MEDICC Rev. 2005;7(5):24–6.

  29. Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-Hernandez K. Prosthetic heart valve thrombosis: pathogenesis, diagnosis and management. Int J Cardiol. 2006 Jun 7;110(1):1–6.

  30. Cáceres-Lóriga FM, Pérez-López H, Morlans-Hernández K, Facundo-Sánchez H, Santos-Gracia J, Valiente-Mustelier J, et al. Thrombolysis as fi rst choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis. 2006 Apr;21(2):185–90.

  31. Cáceres-Lóriga FM, Santos-Gracia J, Pérez-López H. Thrombotic obstruction of a mechanical prosthetic valve in tricuspid position: therapeutic considerations. Tex Heart Inst J. 2009;36(5):505.

  32. Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-Hernández K, Marrero-Mirayaga MA. Thrombolytic treatment as fi rst option in recurrent tricuspid prosthetic valve thrombosis and Ebstein’s anomaly. J Pharm Pharm Sci. 2005;8(2):332–4.

  33. World Health Organization. Integrated Management of Cardiovascular Risk. Report of WHO Meeting, Geneva, July 2002. Non-communicable Diseases and Mental Health [Internet]. 2002 [cited 2010 Jun 28]. 44p. Available from: whqlibdoc.who.int/publications/9241562242.pdf

  34. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008 Jan 15;117(2):296–329.

  35. Danchin N. Systems of care for ST-segment elevation myocardial infarction: impact of different models on clinical outcomes. J Am Coll Cardiol Intv. 2009;2(10):901–8.

  36. Interview with Dr Ricardo Pereda, deputy director SIUM, Havana, Cuba. May 28, 2010.

  37. Sosa A. Organización, estructura y dirección de la urgencia de los cuidados intensivos. In: Caballero A, editor. Terapia intensiva. Tomo I [Internet]. Havana: Editorial Ciencias Médicas; c2006 [cited 2010 May 15]. [about 13 p.]. Available from: http://www.bvs.sld.cu/libros_texto/terapia_intensiva/capitulo03_ nuevo.pdf

  38. These are crude estimates prepared for operational reporting. The epidemiology of AMI is very complex and several challenges have been identifi ed among others: 1. Changing defi nition of MI, 2. Pervasive grouping of ST elevation MI and non-ST elevation into the single category of MI, 3. Diffi culty assessing population denominators. See Yeh RW, Go AS. Rethinking the Epidemiology of Acute Myocardial Infarction. Challenges and Opportunities. Arch Intern Med. 2010;170(9):759–64.

  39. Interview with Dr Caridad Kesser, epidemiologist, ICCCV, Havana, Cuba, February 15, 2010.

  40. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, López- Sendón J, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359(9304):373–7.

  41. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, et al. Thirty-fi ve-year trends in cardiovascular risk factors in Finland. Int J Epidemiol. 2010;39(2):504–18.




2020     |     www.medigraphic.com